Mimedx (MDXG) Free Cash Flow (QoQ) (2011 - 2026)
Mimedx (MDXG) Free Cash Flow (QoQ) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn |
| 10 | Mimedx | 647.97 Mn | 488.19 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -94.69% |
| Dec 31, 2025 | -15.33% |
| Sep 30, 2025 | 104.61% |
| Jun 30, 2025 | 189.31% |
| Mar 31, 2025 | -73.42% |
| Dec 31, 2024 | -9.15% |
| Sep 30, 2024 | -6.10% |
| Jun 30, 2024 | 349.09% |
| Mar 31, 2024 | 649.94% |
| Dec 31, 2023 | -106.26% |
| Sep 30, 2023 | 27.16% |
| Jun 30, 2023 | 1,739.17% |
| Mar 31, 2023 | -83.47% |
| Dec 31, 2022 | 495.08% |
| Sep 30, 2022 | 118.02% |
| Jun 30, 2022 | 67.27% |
| Mar 31, 2022 | 9.68% |
| Dec 31, 2021 | -297.98% |
| Sep 30, 2021 | 384.34% |
| Jun 30, 2021 | 113.85% |